Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
Phase 2
130
about 3.3 years
18–85
2 sites in CT
What this study is about
Researchers are testing whether adding a SGLT2 inhibitor to standard care in hospitalized patients with heart failure and acute kidney injury improves outcomes. The trial will assess if this treatment helps reduce the risk of death, dialysis, worsening kidney function, fluid buildup, and heart failure symptoms. It also compares individual parts of these outcomes and changes in markers related to kidney health.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Dapagliflozin 10mg Tab
- 2.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
ALIMENTARY TRACT AND METABOLISM
oral (Oral Tablet)
Secondary: Change in heart failure symptoms (mobility and self care), Change in slope of blood interleukin-6 (IL-6) over 14 days from enrollment, Change in slope of patient-reported VAS dyspnea score over 14 days from enrollment, Change in slope of serum creatinine over 14 days from enrollment, Change in slope of urine interleukin-6 (IL-6) over 14 days from enrollment, Incidence of adverse events during exposure
Renal, Cardiology / Heart